Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

In Vivo Podcast
• Source: Shutterstock

"My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” 

In this latest instalment of the In Vivo podcast, Treehill Partners founder, CEO and chair Ali Pashazadeh focuses on the need for increased communication between biotech and pharma and their contract organizations (both research and development/manufacturing organizations). Pashazadeh also analyzes how his previous medical experience guides him now, as he attempts to transfer the same ethos held as a doctor and clinician to the world of investment banking.

Timestamps:

  • Introduction - 00:00
  • Clinal development optimization model - 2:37
  • Transferring between industries – 7:06
  • To what extent will AI impact research? - 11:56
  • China and the importance of early data - 15:23
  • Looking ahead - 16:35  

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.